Mirati Therapeutics
9363 Towne Centre Drive
Suite 200
San Diego
California
92121
United States
Tel: 858-535-2075
225 articles with Mirati Therapeutics
-
Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
5/4/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the first quarter of 2022 and recent corporate updates.
-
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
4/27/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Mirati Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Updates
4/20/2022
Mirati Therapeutics, Inc. will announce financial results for the first quarter of 2022 along with recent corporate updates on May 4, 2022.
-
Mirati Therapeutics to Participate in the 42nd Annual Cowen Healthcare Conference
3/2/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Cowen Healthcare Conference.
-
Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
2/28/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year 2021 and recent corporate updates.
-
The NDA acceptance is based on positive results from the KRYSTAL-1 trial, which looked into the effect of using 600mg BID of adagrasib in patients.
-
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
2/15/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022
2/14/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the fourth quarter and full year of 2021 along with recent corporate updates on February 28, 2022.
-
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
2/2/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
-
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers
1/21/2022
Mirati Therapeutics, Inc. today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumors harboring a KRAS mutation.
-
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
-
Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference
1/4/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference, on Monday, January 10, 2022.
-
Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
11/23/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI HealthCONx Conference.
-
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
11/22/2021
Mirati Therapeutics, Inc. announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer.
-
Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.
-
Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers
11/17/2021
Mirati Therapeutics, Inc. today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the Company's synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.
-
Mirati Therapeutics Announces Pricing of Public Offering of Common Stock - Nov 11, 2021
11/11/2021
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced the pricing of an underwritten public offering of 3,448,275 shares of its common stock at a price to the public of $145.00 per share.
-
Mirati Therapeutics Announces Proposed Public Offering of Common Stock - Nov 09, 2021
11/9/2021
Mirati Therapeutics, Inc. a clinical-stage oncology company, announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common stock.
-
Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
11/9/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Stifel Healthcare Conference 2021, which will be webcast on November 16 at 8:20 a.m. P.T. / 11:20 a.m. E.T. David Meek, chief executive officer and Charles Baum, M.D., Ph.D., president, founder and head of research and development, will represent the company.
-
Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
11/8/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2021 and recent corporate updates.